Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertersione, albuminuria, lercanidipina)

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 17, Issue 5, 2004, Pages 259-266

  Dalla Vestra, Michelle ^a   Pozza, G ^b   Mosca, A ^c   Grazioli, V ^d   Lapolla, A ^a   Fioretto, P ^a   Crepaldi, G ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Diabetic nephropathy; Lercanidipine; Microalbuminuria; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTILIPEMIC AGENT; ATENOLOL; HYDROCHLOROTHIAZIDE; INSULIN; LERCANIDIPINE; ORAL ANTIDIABETIC AGENT; RAMIPRIL;

ADULT; AGED; ANKLE EDEMA; ARTICLE; ASTHENIA; BLOOD PRESSURE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPIGASTRIC PAIN; EXCRETION; FEMALE; FLUSHING; FOLLOW UP; HEADACHE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HEART RATE VARIABILITY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PARALLEL DESIGN; PEPTIC ULCER; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RETINA DETACHMENT; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIHYDROPYRIDINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RAMIPRIL; TREATMENT OUTCOME;

EID: 12344323875     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. The United States Renal Data System: URSD Annual Data Report. Bethesda, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000.
2. Caramori M.L., Fioretto P., Mauer M.: The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 49: 1399-1408, 2000.
3. Valmadrid C.T., Klein R., Moss S.E., Klein B.E.: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch. Intern. Med. 160: 1093-1100, 2000.
4. Schmitz A., Vaeth M.: Microalbuminuria: a major risk factor in non insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet. Med. 5: 126-134, 1988.
5. Mogensen C.E.: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 310: 356-360, 1984.
6. Pahor M., Psaty B.M., Alderman M.H., Applegate W.B., Williamson J.D., Furberg C.D.: Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 23: 888-892, 2000.
7. Berl T., Hunsicker L.G., Lewis J.B., Pfeffer M.A., Porush J.G., Rouleau J.L., Drury P.L., Esmatjes E., Hricik D., Parikh C.R., Raz I., Vanhille P., Wiegmann T.B., Wolfe B.M., Locatelli F., Goldhaber S.Z., Lewis E.J., Irbesartan Diabetic Nephropathy Trial Collaborative Study Group: Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with Type 2 diabetes and overt nephropathy. Ann. Intern. Med. 138: 542-549, 2003.
8. Curb J.D., Pressel S.L., Cutler J.A., Savage P.J., Applegate W.B., Black H., Camel G., Davis B.R., Frost P.H., Gonzalez N., Guthrie G., Oberman A., Rutan G.H., Stamler J.: Effect of diuretic-based antihypertensive treatment of cardiovascular disease risk in older diabetic patients with systolic hypertension. J.A.M.A. 276: 1886-1892, 1996.
9. Tuomilehto J., Rastenyte D., Birkenhager W.H., Thijs L., Antikainen R., Bulpitt C.J., Fletcher A.E., Forette F., Goldhaber A., Palatini P., Sarti C., Fagard R.: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N. Engl. J. Med. 340: 677-684, 1999.
10. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE substudy. Lancet 335: 253-259, 2000.
11. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., Menard J., Rahn K.H., Wedel H., Westerling S.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351: 1755-1762, 1998.
12. UK Prospective Diabetews Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complication in type 2 diabetes. UKPDS 39. B.M.J. 317: 713-720, 1998.
13. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D.: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329: 1456-1462, 1993.
14. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I., for the Collaborative Study Group: Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345: 851-860, 2001.
15. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mithch W.E., Parving H-H., Remuzzi G., Snapinn S.M., Zhang Z., Shahinfar S., for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345: 861-869, 2001.
16. Parving H-H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P., for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345: 870-878, 2001.
17. Fogari R., Zoppi A., Malamani G.D., Effects Fogari R., Zoppi A., Corradi L., Mugellini A., Lazzari P., Preti P., Lusardi P.: Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J. Hum. Hypertens. 13: 47-53, 1999.
18. Fogari R., Preti P., Zoppi A., Rinaldi A., Corradi L., Pasotti C., Poletti L., Marasi G., Derosa G., Mugellini A., Voglini C., Lazzari P.: Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am. J. Hypertens. 15: 1042-1049, 2002.
19. Velussi M., Brocco E., Frigato F., Zolli M., Muollo B., Maioli M., Carraro A., Tonolo G., Fresu P., Cernigoi A.M., Fioretto P., Nosadini R.: Effects of cilazapril and amlodipine on kidney function in hypertyensive NIDDM patients. Diabetes 45: 216-222, 1996.
20. Ruggenenti P., Perna A., Gherardi G., Benini R., Remuzzi G.: Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am. J. Kidney. Dis. 35: 1155-1165, 2000.
21. Estacio R.O., Jeffers B.W., Hiatt W.H., Biggerstaff S.L., Gifford N., Schrier R.W.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non insulin dependent diabetes and hypertension. N. Engl. J. Med. 338: 645-652, 1998.
22. Chan JC, Cockram C, Nicholls M, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipine in treating non insulin dependent diabetes associated with hypertension: one year analysis. B.M.J. 305: 981-985, 1992.
23. Bakris G., Copley J., Vicknair N., Sadler R., Leurgans S.: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 50: 1641-1650, 1996.
24. Viberti G., Wheeldon N.M., for the MARVAL Study Investigators. Microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 106: 672-678, 2002.
25. Lindholm L., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., Snapinn S., The LIFE Study Group: Cardiovascular morbility and mortality in patients with diabetes mellitus in the Losartan Intervention For End point reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 359: 1004-1010, 2002.
26. Hansson L., Lindholm L., Ekbom T., Dahlof B., Lanke J., Schersten B., Wester P.O., Hedner T., de Faire U.: Randomized trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbility the Swedish Trial in Old Patients with hypertension-2 study. Lancet 354: 1751-1744, 1999.